Drug Profile
Research programme: cannabinoid based therapeutics - SciSparc
Alternative Names: Dronabinol/palmitoylethanolamide combination therapies - SciSparc; Palmitoylethanolamide; Palmitoylethanolamide combination therapies - SciSparc; THX 120; THX-ULD01Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Dekel Pharmaceuticals
- Developer SciSparc
- Class Analgesics; Antibacterials; Cannabinoids; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Opioid-related disorders
- Research Gilles de la Tourette's syndrome; Inflammation
Most Recent Events
- 07 Mar 2024 SciSparc has patent protection for composition of cannabinoids and n-acylethanolamines and methods of use in cannabinoid-treated conditions in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the UK
- 07 Mar 2024 SciSparc has patent protection for composition of cannabinoids and n-acylethanolamines and methods of use in cannabinoid-treated conditions in Japan and other jurisdictions
- 08 Nov 2022 SciSparc has patent protection for compositions and methods of potentiating antimicrobials in USA